论文部分内容阅读
将灭活的自身黑色素瘤细胞MEL 72与BCG混合免疫MEL 72黑色素瘤病人 ,10d后手术方法获取局部引流淋巴结 ,制成淋巴细胞悬液 ,以抗CD3抗体体外培养 ,ELISA方法检测细胞上清中肿瘤特异性Th1、Th2细胞因子的表达。进一步用抗OX 40抗体与CD4+ T淋巴细胞表面OX 40作用或用抗IL 4抗体阻断IL 4的分泌 ,观察肿瘤特异性免疫反应能否向Th1方向转换。结果表明 :用灭活的自体肿瘤细胞免疫机体能诱导出该肿瘤细胞特异性的Th1和Th2。应用抗OX 40抗体与抗IL 4抗体作用后 ,Th1细胞因子分泌水平增加 (TNF β和IFN γ ) ,结果提示 ,应用抗OX 40和抗IL 4抗体可诱导肿瘤特异性Th1反应。
The inactivated melanoma cells MEL 72 were mixed with BCG to immunize MEL 72 melanoma patients. After 10 days, the local draining lymph nodes were obtained by surgical method to make lymphocyte suspension. The anti-CD3 antibody was cultured in vitro and detected by ELISA Tumor specific Th1, Th2 cytokine expression. The effect of anti-OX40 antibody on the surface of CD4 + T lymphocytes OX40 or the anti-IL4 antibody was used to block the secretion of IL4 to observe whether the tumor-specific immune responses could switch to Th1. The results showed that the tumor-specific Th1 and Th2 can be induced by in vivo immunization with inactivated autologous tumor cells. Increased levels of Th1 cytokines (TNF [beta] and IFN [gamma]) after anti-OX40 and anti-IL4 antibodies are applied suggest that tumor-specific Thl responses can be induced using anti-OX40 and anti-IL4 antibodies.